<DOC>
	<DOCNO>NCT00437970</DOCNO>
	<brief_summary>This study compare metformin ( current first-line medication ) pioglitazone ( new diabetic medication currently approve combination use ) . Whilst good evidence benefit pioglitazone use population , light know weight gain effect pioglitazone believe assessment require Indigenous Australians ( strong predisposition central fat deposition ) . This study provide evidence regard medication appropriate first line medication Type 2 diabetes high risk population . This study assist clinician make evidenced-based decision regard initial medical management Type 2 diabetes ( currently gap evidence ) .</brief_summary>
	<brief_title>Medication Early Diabetes ( MED ) Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Drug na√Øve Indigenous Australians Type 2 Diabetes Permanent resident Darwin least 1 year immediately expect least 1 year study commences Participants must able give informed voluntary consent Both male female ( female child bear potential exclude reliable mean contraception )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>